Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Molecular Markers in Lung Cancer: Dr. Charlie Rudin on the Lung Cancer Mutation Consortium
Author
Howard (Jack) West, MD

This is the first of a series of podcasts from the two hour special webinar we did in partnership with the LUNGevity Foundation at the Santa Monica "Targeted Therapies in Lung Cancer" meeting several weeks ago.  There, I was privileged to be joined by four excellent guest faculty members -- Dr. Charles Rudin from Johns Hopkins University in Baltimore, Dr. Alice Shaw from Massachusetts General Hospital in Boston, Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, and Dr. Glen Goss from the University of Ottawa.  They each brought their rich experience and some differing perspectives on the complex and evolving topic of how to apply new work on molecular markers in lung cancer to clinical practice.

Below you'll find links to the audio and video versions of the podcast, along with the transcript and figures.

[powerpress]

Molecular Markers SM Pt 1 Rudin on LCMC Audio Podcast

Molecular Markers SM Pt 1 Rudin on LCMC Transcript

Molecular Markers SM Pt 1 Rudin on LCMC Figures

This program also includes additional discussion before and after his presentation, as the webinar featured both presentations by the guest faculty and a panel discussion about the most timely questions in the field.  It was a lot of fun for me and our panel, and I hope you find it both interesting and educational.

The next part will be Dr. Shaw speaking on their experience of broadly molecularly profiling their patients at Massachusetts General Hospital for markers and what they've learned from that work.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora